Evading Capture by Residual Disease Monitoring: Extramedullary Manifestation of JAK2 V617F-Positive Primary Myelofibrosis After Allogeneic Stem Cell Transplantation
Monitoring of the JAK2 V617F allele burden in myeloproliferative neoplasms after allogeneic stem cell transplantation is useful to determine levels of residual disease and has the potential to detect early relapse and guide subsequent clinical intervention. A case is described of a JAK2 V617F-positi...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2015/703457 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551626605330432 |
|---|---|
| author | Stephen E. Langabeer James Nolan Karl Haslam Lindsey Clarke Richard Flavin Eibhlin Conneally |
| author_facet | Stephen E. Langabeer James Nolan Karl Haslam Lindsey Clarke Richard Flavin Eibhlin Conneally |
| author_sort | Stephen E. Langabeer |
| collection | DOAJ |
| description | Monitoring of the JAK2 V617F allele burden in myeloproliferative neoplasms after allogeneic stem cell transplantation is useful to determine levels of residual disease and has the potential to detect early relapse and guide subsequent clinical intervention. A case is described of a JAK2 V617F-positive primary myelofibrosis patient who underwent allogeneic stem cell transplantation. Prospective residual disease monitoring of the peripheral blood failed to detect an extramedullary manifestation of the disease, a periorbital myeloid sarcoma, arising nearly three years after transplant. This case serves to highlight a pitfall in residual disease monitoring for myeloproliferative neoplasm-associated mutations in the post-allogeneic stem cell transplantation setting. |
| format | Article |
| id | doaj-art-b8855ef5b84240e1ba37882dfb928e26 |
| institution | Kabale University |
| issn | 2090-6560 2090-6579 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hematology |
| spelling | doaj-art-b8855ef5b84240e1ba37882dfb928e262025-02-03T06:01:03ZengWileyCase Reports in Hematology2090-65602090-65792015-01-01201510.1155/2015/703457703457Evading Capture by Residual Disease Monitoring: Extramedullary Manifestation of JAK2 V617F-Positive Primary Myelofibrosis After Allogeneic Stem Cell TransplantationStephen E. Langabeer0James Nolan1Karl Haslam2Lindsey Clarke3Richard Flavin4Eibhlin Conneally5Cancer Molecular Diagnostics, St. James’s Hospital, Dublin 8, IrelandDepartment of Haematology, St. James’s Hospital, Dublin 8, IrelandCancer Molecular Diagnostics, St. James’s Hospital, Dublin 8, IrelandDepartment of Histopathology, St. James’s Hospital, Dublin 8, IrelandDepartment of Histopathology, St. James’s Hospital, Dublin 8, IrelandDepartment of Haematology, St. James’s Hospital, Dublin 8, IrelandMonitoring of the JAK2 V617F allele burden in myeloproliferative neoplasms after allogeneic stem cell transplantation is useful to determine levels of residual disease and has the potential to detect early relapse and guide subsequent clinical intervention. A case is described of a JAK2 V617F-positive primary myelofibrosis patient who underwent allogeneic stem cell transplantation. Prospective residual disease monitoring of the peripheral blood failed to detect an extramedullary manifestation of the disease, a periorbital myeloid sarcoma, arising nearly three years after transplant. This case serves to highlight a pitfall in residual disease monitoring for myeloproliferative neoplasm-associated mutations in the post-allogeneic stem cell transplantation setting.http://dx.doi.org/10.1155/2015/703457 |
| spellingShingle | Stephen E. Langabeer James Nolan Karl Haslam Lindsey Clarke Richard Flavin Eibhlin Conneally Evading Capture by Residual Disease Monitoring: Extramedullary Manifestation of JAK2 V617F-Positive Primary Myelofibrosis After Allogeneic Stem Cell Transplantation Case Reports in Hematology |
| title | Evading Capture by Residual Disease Monitoring: Extramedullary Manifestation of JAK2 V617F-Positive Primary Myelofibrosis After Allogeneic Stem Cell Transplantation |
| title_full | Evading Capture by Residual Disease Monitoring: Extramedullary Manifestation of JAK2 V617F-Positive Primary Myelofibrosis After Allogeneic Stem Cell Transplantation |
| title_fullStr | Evading Capture by Residual Disease Monitoring: Extramedullary Manifestation of JAK2 V617F-Positive Primary Myelofibrosis After Allogeneic Stem Cell Transplantation |
| title_full_unstemmed | Evading Capture by Residual Disease Monitoring: Extramedullary Manifestation of JAK2 V617F-Positive Primary Myelofibrosis After Allogeneic Stem Cell Transplantation |
| title_short | Evading Capture by Residual Disease Monitoring: Extramedullary Manifestation of JAK2 V617F-Positive Primary Myelofibrosis After Allogeneic Stem Cell Transplantation |
| title_sort | evading capture by residual disease monitoring extramedullary manifestation of jak2 v617f positive primary myelofibrosis after allogeneic stem cell transplantation |
| url | http://dx.doi.org/10.1155/2015/703457 |
| work_keys_str_mv | AT stephenelangabeer evadingcapturebyresidualdiseasemonitoringextramedullarymanifestationofjak2v617fpositiveprimarymyelofibrosisafterallogeneicstemcelltransplantation AT jamesnolan evadingcapturebyresidualdiseasemonitoringextramedullarymanifestationofjak2v617fpositiveprimarymyelofibrosisafterallogeneicstemcelltransplantation AT karlhaslam evadingcapturebyresidualdiseasemonitoringextramedullarymanifestationofjak2v617fpositiveprimarymyelofibrosisafterallogeneicstemcelltransplantation AT lindseyclarke evadingcapturebyresidualdiseasemonitoringextramedullarymanifestationofjak2v617fpositiveprimarymyelofibrosisafterallogeneicstemcelltransplantation AT richardflavin evadingcapturebyresidualdiseasemonitoringextramedullarymanifestationofjak2v617fpositiveprimarymyelofibrosisafterallogeneicstemcelltransplantation AT eibhlinconneally evadingcapturebyresidualdiseasemonitoringextramedullarymanifestationofjak2v617fpositiveprimarymyelofibrosisafterallogeneicstemcelltransplantation |